Remission of acquired von Willebrand syndrome in a patient with chronic lymphocytic leukemia treated with venetoclax

Leuk Lymphoma. 2019 Dec;60(12):3078-3080. doi: 10.1080/10428194.2019.1612063. Epub 2019 May 20.

Authors

Affiliations

¹ Institute of Hematology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
² Institute of Hematology, Universita Cattolica del Sacro Cuore, Rome, Italy.

PMID: 31106622
DOI: 10.1080/10428194.2019.1612063

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use*
Bridged Bicyclo Compounds, Heterocyclic / administration & dosage
Bridged Bicyclo Compounds, Heterocyclic / adverse effects
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use*
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Male
Remission Induction
Sulfonamides / administration & dosage
Sulfonamides / adverse effects
Sulfonamides / therapeutic use*
Treatment Outcome
von Willebrand Diseases / blood
von Willebrand Diseases / complications*
von Willebrand Diseases / diagnosis

Substances

Antineoplastic Agents
Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax